Last update Feb. 5, 2022

Sodium Thiosulphate

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Inorganic compound that is used in systemic administration as an antidote for cyanide poisoning and in extravasations of certain antineoplastic drugs and, used topically, as an antifungal. It has been used in infants from one month of age.

At the date of the last update, there was no published data available on its excretion in human milk. 

Its pharmacokinetic data do not allow to predict whether it’s possible for it to be excreted in breastmilk. 

Its low oral bioavailability (Farese 2011) makes it difficult for the infant to pass into plasma from ingested mothers’ milk, except in premature infants and during the immediate neonatal period in which there may be greater intestinal permeability.

Given its short half-life (Shea 1984), it is possible to breastfeed again 6 hours after the last administration of the drug if the mother's clinical status allows it.

WHO List of Essential Medicines: topical dermatological application of sodium thiosulfate is compatible with breastfeeding.(WHO 2002)

Alternatives

We do not have alternatives for Sodium Thiosulphate.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Sodium Thiosulphate is also known as


Sodium Thiosulphate in other languages or writings:

Tradenames

Main tradenames from several countries containing Sodium Thiosulphate in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 8 (1 - 26) %
Molecular weight 248 daltons
VD 0.15 l/Kg
pKa 11.35 -
1.3 (0.3 – 2) hours

References

  1. Farese S, Stauffer E, Kalicki R, Hildebrandt T, Frey BM, Frey FJ, Uehlinger DE, Pasch A. Sodium thiosulfate pharmacokinetics in hemodialysis patients and healthy volunteers. Clin J Am Soc Nephrol. 2011 Jun;6(6):1447-55. Abstract
  2. WHO / UNICEF. BREASTFEEDING AND MATERNAL MEDICATION Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. Department of Child and Adolescent Health and Development (WHO/UNICEF) 2002 Full text (link to original source) Full text (in our servers)
  3. Shea M, Koziol JA, Howell SB. Kinetics of sodium thiosulfate, a cisplatin neutralizer. Clin Pharmacol Ther. 1984 Mar;35(3):419-25. Abstract

Total visits

4,781

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM